Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.81 |
| ▸ | MMP2 | P08253 | 12/20 | 0.81 |
| ▸ | MMP8 | P22894 | 12/20 | 0.81 |
| ▸ | MMP7 | P09237 | 3/20 | 0.66 |
| ▸ | MMP12 | P39900 | 1/20 | 0.66 |
| ▸ | MMP13 | P45452 | 1/20 | 0.66 |
| ▸ | MMP1 | P03956 | 5/20 | 0.63 |
| ▸ | FCER2 | P06734 | 4/20 | 0.63 |
| ▸ | MMP3 | P08254 | 2/20 | 0.63 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | ANPEP | P15144 | 1/20 | 0.58 |
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29730834 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL8740490 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL13274328 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL12561524 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL29379670 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL1847906 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL8858284 | 0.91 | MMP2 (0.89) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL13478923 | 0.91 | MMP2 (0.79) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL5556836 | 0.89 | MMP2 (1.00) | MMP9MMP2MMP8MMP7MMP12 | |
| SCHEMBL5552919 | 0.89 | MMP2 (1.00) | MMP9MMP2MMP8MMP7MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093216-B2 | Diagnosis and classification of cancer; obtain tissue sample, lyse cells, screen lysate for expression of tumor polypeptide, presence of polypeptide indicates tumor | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2012-01-10 | — | — | US | claimed |
| US-5629285-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-05-13 | — | — | US | claimed |
| EP-0715619-A4 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORP (US) | 1997-03-19 | — | — | EP | claimed |
| US-5594106-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-01-14 | — | — | US | claimed |
| EP-0715619-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1995006031-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1995-03-02 | — | — | WO | claimed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-5853977-A | Mammalian TNF-α convertases | SCHERING CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998039449-A1 | COMPOSITIONS AND USE OF M-CSF-alpha | CHIRON CORPORATION (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998002557-A2 | MAMMALIAN TNF-α CONVERTASES | SCHERING CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5629285-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-05-13 | — | — | US | disclosed |
| US-5594106-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1995006031-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |